Aduro Biotech has announced a restructuring plan to further extend the company’s operating capital and align personnel towards executing its clinical development strategy. Following a detailed review of its operations and growth opportunities, Aduro intends to reduce its current workforce by roughly 59% across the organization, minimize its corporate facilities footprint and shut down the Aduro Biotech Europe headquarters in Oss, The Netherlands by the end of the third quarter of 2020. The reduction in ongoing operating expenses is expected to extend the Company’s cash runway. Learn More